BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.12 USD | +2.17% |
|
-0.28% | -19.85% |
| May. 30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
| May. 30 | Bristol Myers: FDA approval for Breyanzi | CF |
ETFs positioned on Bristol-Myers Squibb Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 254 M€ | +13.69% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 17 M€ | +6.09% | - | |
| 2.63% | 23 M€ | +14.32% | - | |
| 2.37% | 2 M€ | -25.75% | ||
| 2.29% | 31 M€ | +1.53% | - | |
| 2.08% | 9 M€ | -.--% | - | |
| 1.90% | 16 M€ | -3.37% | ||
| 1.85% | 2 M€ | -.--% | ||
| 1.43% | 5 M€ | -72.95% | - | |
| 1.42% | 9 M€ | -4.31% | - | |
| 1.37% | 26 M€ | +16.85% | - | |
| 1.26% | 800 M€ | +5.69% | ||
| 1.00% | 85 M€ | -0.54% | ||
| 0.99% | 9 M€ | +9.41% | ||
| 0.83% | 104 M€ | +9.50% | ||
| 0.82% | 8 M€ | -.--% | ||
| 0.80% | 2,383 M€ | +13.18% | ||
| 0.78% | 3 M€ | +15.16% | - | |
| 0.78% | 13 M€ | -.--% | - |
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.85% | 83.29B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- BMY Stock
- Funds and ETFs Bristol-Myers Squibb Company
